First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial
First-line serplulimab provided a sustained clinical benefit over placebo in patients with ES-SCLC. A 15-protein signature and mutations in RB1 or Notch pathway genes may serve as predictive biomarkers for benefits from serplulimab plus chemotherapy, while baseline NLR and LDH were independent prognosticators for ES-SCLC.
Authors
- Yueyin Pan (ORCID: https://orcid.org/0000-0003-0532-5368)
- Guilan Wen
- Ekaterine Arkania
- Peiyan Zhao (ORCID: https://orcid.org/0000-0002-6977-339X)
- Maksym Viguro
- Yongqiang Shan
- Yanqiu Zhao (ORCID: https://orcid.org/0009-0009-8085-2302)
- Tamar Melkadze (ORCID: https://orcid.org/0000-0003-0800-6514)
- Jun Zhu (ORCID: https://orcid.org/0000-0003-1824-7610)
- Ying Cheng (ORCID: https://orcid.org/0000-0001-9908-597X)
- Jinsheng Shi (ORCID: https://orcid.org/0000-0003-2219-5956)
- Tamta Makharadze
- Fang Yang (ORCID: https://orcid.org/0000-0003-3465-6465)
- Lin Wu (ORCID: https://orcid.org/0000-0001-7078-7767)
- Shuang Zhang (ORCID: https://orcid.org/0000-0002-4009-3403)
- Jing Li (ORCID: https://orcid.org/0000-0001-8079-2121)
- Ling Chen (ORCID: https://orcid.org/0000-0003-1485-1626)
- Jianhua Shi (ORCID: https://orcid.org/0009-0006-1914-9691)
- Jun Chen (ORCID: https://orcid.org/0000-0002-2362-5359)
- Haoyu Yu
- Xinyi Yang (ORCID: https://orcid.org/0009-0002-6301-359X)
- Hongmei Sun (ORCID: https://orcid.org/0000-0003-1383-5720)
- Yinghua Ji
- Xuhong Min (ORCID: https://orcid.org/0000-0001-6498-3278)
- Zhijie Pan (ORCID: https://orcid.org/0000-0002-7605-780X)
- Xicheng Wang (ORCID: https://orcid.org/0000-0001-6677-850X)
- Liang Han (ORCID: https://orcid.org/0000-0002-2803-7804)
- XingYa Li
- Yuansong Bai (ORCID: https://orcid.org/0000-0002-3596-0138)
- Junquan Yang (ORCID: https://orcid.org/0000-0003-1326-1093)
- Anastasia Zimina
- Qingyu Wang (ORCID: https://orcid.org/0009-0003-7496-147X)
Institutions
- Apple (Israel) (IL)
- Union Hospital (HK)
- Central South University (CN)
- Nanchang University (CN)
- Jiamusi University (CN)
- Jilin University (CN)
- State University of Medan (ID)
- Israel Medical Association (IL)
- Batumi State Maritime Academy (GE)
- Tianjin Medical University General Hospital (CN)
- Zhengzhou University (CN)
- Clinical Research Institute (US)
- Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center" (RU)
- Highland Hospital (US)
- Tangshan People's Hospital (CN)
- Linyi People's Hospital (CN)
- Jilin Province Tumor Hospital (CN)
- First Affiliated Hospital of Jiamusi University (CN)
- People's Hospital of Cangzhou (CN)
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Hunan Cancer Hospital (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Anhui Provincial Hospital (CN)
- Linzhou Cancer Hospital (CN)
- Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital (RU)
- Xuzhou Central Hospital (CN)
- David Tvildiani Medical University (GE)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Viva Biotech (China) (CN)
- Xi'an Chest Hospital (CN)
- Union Hospital (CN)
- First Affiliated Hospital of Nanchang University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Tbilisi State Medical University (GE)
- Henan Medical University (CN)
Publication Details
- Journal
- Cancer Communications
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1002/cac2.70032
- Citations
- 8
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- National Natural Science Foundation of China